Regeneron Pharmaceuticals (REGN) is about to have a chance to prove that its pricey, seldom-used cardiovascular drug can actually improve patients’ lives — an outcome that would also allow it to remove the air quotes from its “blockbuster” product.

Some time this quarter, Regeneron will release clinical trial data showing whether Praluent, an injected therapy that blasts away bad cholesterol, is better than yesteryear drugs at preventing heart attack, stroke, and hospitalization. That will determine whether the company can compete with Amgen (AMGN), its bitter rival in marketplace and courtroom alike.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.